A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease
Phase 4
400
about 3.2 years
18–80
98 sites in AL, AR, AZ +29
About this study
This trial is testing how many adults with ulcerative colitis (UC) or Crohn's disease (CD) will have their symptoms disappear after 3.5 months of treatment with Vedolizumab, a medication given as an infusion and then by injection for the rest of it period. Participants will visit the clinic several times during it.
Based on ClinicalTrials.gov records.
What participants do
- 1.Receive Vedolizumab IV
- 2.Take Vedolizumab SC
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
vedolizumab
injection, intravenous, infusion
Primary: Percentage of CD Participants With 2-item Patient-reported Outcome Measure (PRO-2) Remission at Week 14, Percentage of UC Participants With PRO-2 Remission at Week 14
Secondary: Change From Baseline in C-reactive Protein (CRP) levels of CD and UC Participants at Weeks 6, 14, and 52, Change From Baseline in Fecal Calprotectin Concentrations of CD and UC participants at Weeks 6, 14, and 52, Percentage of CD and UC Participants With PRO-2 Remission at Weeks 6 and 52
Gastroenterology